A study in humans identified the miR-103a-2-5p as up-regulated in STEMI patients via small RNA sequencing [Tong et al. DOI:10.3390/ijms19051467]. Another human study investigating recurrent myocardial infarction risk after percutaneous coronary intervention found the miR-103a-2-5p was down-regulated in whole blood of patients with recurrent events, with this differential expression remaining significant after false-discovery rate correction [Onuoha et al. DOI:10.1111/cts.13307].